Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amiloride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A known ✓ | P37088 | 1/20 | 0.93 |
| ▸ | PLAU | P00749 | 11/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.93 |
| ▸ | SLC9A1 | P19634 | 6/20 | 0.93 |
| ▸ | TSHR | P16473 | 5/20 | 0.93 |
| ▸ | SLC9A5 | Q14940 | 5/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.93 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.93 |
| ▸ | GLA | P06280 | 3/20 | 0.93 |
| ▸ | HPGD | P15428 | 3/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.93 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.93 |
| ▸ | GAA | P10253 | 2/20 | 0.93 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.93 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.93 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.93 |
| ▸ | BLM | P54132 | 2/20 | 0.93 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amiloride SCHEMBL871514 | 0.98 | PLAU (0.90) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| Amiloride SCHEMBL29531132 | 0.96 | PLAU (1.00) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| Amiloride SCHEMBL27563 | 0.96 | PLAU (1.00) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| Amiloride SCHEMBL4155066 | 0.95 | ALDH1A1 (1.00) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL2690754 | 0.87 | PLAU (0.83) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL13902826 | 0.83 | PLAU (0.75) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL14153334 | 0.83 | PLAU (0.75) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL15033062 | 0.83 | PLAU (0.75) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL10087514 | 0.81 | PLAU (0.73) | PLAUCYP1A2SLC9A1TSHRSLC9A5 | |
| SCHEMBL13104159 | 0.80 | PLAU (0.71) | PLAUCYP1A2SLC9A1TSHRSLC9A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115612114-B | Copolymer membrane and method for enzymatic self-assembly synthesis and application thereof | 中国科学院天津工业生物技术研究所 | 2024-02-20 | — | — | CN | disclosed |
| CN-115612403-B | Self-assembled strong-adhesion copolymer film, coating method and application | 中国科学院天津工业生物技术研究所 | 2023-12-01 | — | — | CN | disclosed |
| US-20230233552-A1 | COMPOSITIONS FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2023-07-27 | — | — | US | disclosed |
| US-11672796-B2 | Compositions for treating CMT and related disorders | PHARNEXT (FR) | 2023-06-13 | — | — | US | disclosed |
| US-11576908-B2 | Compositions for treating CMT and related disorders | PHARNEXT (FR) | 2023-02-14 | — | — | US | disclosed |
| WO-2023284777-A1 | COPOLYMER FILM, ENZYME CATALYSIS SELF-ASSEMBLY SYNTHESIS METHOD THEREFOR, AND APPLICATION THEREOF | 中国科学院天津工业生物技术研究所 | 2023-01-19 | — | — | WO | disclosed |
| CN-115612699-A | Copolymer membrane and enzymatic self-assembly synthesis method and application thereof at gas-liquid interface | 中国科学院天津工业生物技术研究所 | 2023-01-17 | — | — | CN | disclosed |
| CN-115612114-A | Copolymer membrane and enzymatic self-assembly synthesis method and application thereof | 中国科学院天津工业生物技术研究所 | 2023-01-17 | — | — | CN | disclosed |
| CN-115612403-A | Self-assembly strong-adhesion copolymer film, film coating method and application | 中国科学院天津工业生物技术研究所 | 2023-01-17 | — | — | CN | disclosed |
| US-11291670-B2 | Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis | PHARNEXT (FR) | 2022-04-05 | — | — | US | disclosed |
| CN-102065898-A | Novel therapeutic approaches for treating alzheimer's disease and related disorders by modulating angiogenesis | PHARNEXT | 2011-05-18 | — | — | CN | disclosed |
| CN-102065897-A | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response | PHARNEXT | 2011-05-18 | — | — | CN | disclosed |
| EP-2263665-A1 | New compositions for treating CMT and related disorders | Pharnext (FR) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010139627-A1 | NEW COMPOSITIONS FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2010-12-09 | — | — | WO | disclosed |
| US-20100310641-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2010-12-09 | — | — | US | disclosed |
| CN-101883561-A | Novel therapeutic methods for treating CMT and related diseases | PHARNEXT | 2010-11-10 | — | — | CN | disclosed |
| EP-2211846-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009068668-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2009-06-04 | — | — | WO | disclosed |
| EP-2021502-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | Oy Jurilab Ltd (FI) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007128884-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | OY JURILAB LTD (FI) | 2007-11-15 | — | — | WO | disclosed |